| Literature DB >> 34915771 |
G Shiny Chrism Queen Nesan1, D Keerthana1, Raja Yamini1, Timsi Jain1, Dinesh Kumar1, Ananth Eashwer1, G Rakesh Maiya1.
Abstract
OBJECTIVES: Post-COVID-19 symptoms and its features in many recovered patients are almost similar to post-severe acute respiratory syndrome. The study aims to assess the outcome and manifestations during post-COVID follow-up period in recovered patients.Entities:
Keywords: COVID-19; anxiety; follow-up; mood changes; symptoms; tiredness
Mesh:
Year: 2021 PMID: 34915771 PMCID: PMC8721686 DOI: 10.1177/00469580211060165
Source DB: PubMed Journal: Inquiry ISSN: 0046-9580 Impact factor: 1.730
Figure 1.Flow diagram representing procedure involved in selection of study subjects.
Baseline details of the study subjects based on the severity of disease on admission (N = 1354).
| Characteristics | Severity of disease on admission | |||
|---|---|---|---|---|
| Mild | Moderate | Severe | Total | |
| N = 1150 | N = 141 | N = 63 | N = 1354 | |
| N (%) | N (%) | N (%) | N (%) | |
| Age (years) | ||||
| ≤10 | 3 (.2%) | 1 (.1%) | 1 (.1%) | 5 (.4%) |
| 11–20 | 44 (3.2%) | 6 (.4%) | 1 (.1%) | 51 (3.8%) |
| 21–30 | 329 (24.3%) | 34 (2.5%) | 11 (.8%) | 374 (27.6%) |
| 31–40 | 178 (13.1%) | 24 (1.8%) | 3 (.2%) | 205 (15.1%) |
| 41–50 | 176 (13.0%) | 24 (1.8%) | 12 (.9%) | 212 (15.7%) |
| 51–60 | 205 (15.1%) | 32 (2.4%) | 17 (1.3%) | 254 (18.8%) |
| ≥60 | 215 (15.9%) | 20 (1.5%) | 18 (1.3%) | 253 (18.7%) |
| Sex | ||||
| Male | 842 (62.2%) | 98 (7.25) | 49 (3.6%) | 989 (73.0%) |
| Female | 308 (22.7%) | 43 (3.2%) | 14 (1.0%) | 365 (27.0%) |
| Existed comorbidities | ||||
| Diabetes mellitus (DM) | 116 (8.6%) | 15 (1.1%) | 1 (.1%) | 132 (9.7%) |
| Hypertension (HTN) | 41 (3.0%) | 5 (.4%) | 3 (.2%) | 49 (3.6%) |
| Both (DM + HTN) | 71 (5.2%) | 11 (.8%) | 4 (.3%) | 86 (6.4%) |
| Chronic kidney disease | 4 (.3%) | 1 (.1%) | 2 (.1%) | 7 (.5%) |
| Coronary artery disease | 3 (.2%) | 0 | 0 | 3 (.2%) |
| Chronic obstructive pulmonary disease | 8 (.6%) | 0 | 1 (.1%) | 9 (.7%) |
| Asthma | 5 (.4%) | 1 (.1%) | 1 (.1%) | 7 (.5%) |
| Pulmonary tuberculosis | 1 (.1%) | 0 | 0 | 1 (.1%) |
| Hypothyroidism | 7 (.5%) | 0 | 0 | 7 (.5%) |
| Autoimmune conditions | 2 (.1%) | 0 | 0 | 2 (.1%) |
| None | 892 (65.8%) | 108 (7.9%) | 51 (3.7%) | 1051 (77.6%) |
| Type of care received | ||||
| General hospital admission | 1134 (83.8%) | 139 (10.3%) | 58 (4.3%) | 1331 (98.3%) |
| Hospital admission to home care | 3 (.2%) | 0 | 0 | 3 (.2%) |
| ICU stay | 13 (1.0%) | 2 (.1%) | 5 (.4%) | 20 (1.5%) |
| Duration of hospital stay | ||||
| <10 days | 924 (68.3%) | 98 (7.2%) | 24 (1.8%) | 1046 (77.4%) |
| 11–15 days | 195 (14.4%) | 36 (2.7%) | 19 (1.4%) | 250 (18.5%) |
| 16–30 days | 28 (2.1%) | 6 (.4%) | 16 (1.2%) | 50 (3.7%) |
| >1 Month | 2 (.1%) | 0 | 4 (.3%) | 6 (.4%) |
| Condition on discharge | ||||
| Stable with No support | 1129 (83.4%) | 126 (9.3%) | 53 (3.9%) | 1308 (96.6%) |
| Stable with minimal support | 21 (1.6%) | 12 (.9%) | 10 (.7%) | 43 (3.2%) |
| Wheel chair assisted | 0 | 3 (.2%) | 0 | 3 (.2%) |
ICU, intensive care unit.
Gender-based distribution of post-COVID symptoms as reported by the study subjects in the order of descend (N = 1354).
| S.NO | Post-COVID symptoms | Gender | Total N (%) | |
|---|---|---|---|---|
| Male N (%) | Female N (%) | |||
| 1 | Tiredness/fatigue | 400 (29.5%) | 138 (10.2%) | 538 (39.7%) |
| 2 | Stress and anxiety | 268 (19.8%) | 106 (7.8%) | 374 (27.6%) |
| 3 | Change in mood | 56 (4.1%) | 23 (1.7%) | 79 (5.8%) |
| 4 | Myalgia | 51 (3.8%) | 18 (1.3%) | 69 (5.1%) |
| 5 | Loss of appetite | 36 (2.7%) | 16 (1.2%) | 52 (3.8%) |
| 6 | Sleep disturbances | 42 (3.1%) | 7 (.5%) | 49 (3.6%) |
| 7 | Muscular weakness | 32 (2.4%) | 10 (.7%) | 42 (3.1%) |
| 8 | Constipation | 20 (1.5%) | 15 (1.1%) | 35 (2.6%) |
| 9 | Loss of taste | 29 (2.1%) | 5 (.4%) | 34 (2.5%) |
| 10 | Nausea and vomiting | 19 (1.4%) | 12 (.9%) | 31 (2.3%) |
| 11 | Loss of smell | 18 (1.3%) | 5 (.4%) | 23 (1.7%) |
| 12 | Headache | 18 (1.3%) | 4 (.3%) | 22 (1.6%) |
| 13 | Abdominal discomfort | 13 (1.0%) | 1 (.1%) | 14 (1%) |
| 14 | Breathing difficulty | 12 (.9%) | 2 (.1%) | 14 (1%) |
| 15 | Confusion | 9 (.7%) | 4 (.3%) | 13 (1%) |
| 16 | Numbness | 9 (.7%) | 1 (.1%) | 10 (.7%) |
| 17 | Sore throat | 7 (.5%) | 2 (.1%) | 9 (.7%) |
| 18 | Chest pain | 6 (.4%) | 2 (.1%) | 8 (.6%) |
| 19 | Palpitations | 6 (.4%) | 1 (.1%) | 7 (.5%) |
| 20 | Burning and pricking pain sensation on body | 5 (.4%) | 1 (.1%) | 6 (.4%) |
| 21 | Reduced urine output | 4 (.3%) | 0 | 4 (.3%) |
Association between months of admission and system-based post-discharge symptoms (N = 1354).
| Months of admission 2020 | General symptoms N (%) | Cardio-respiratory symptoms N (%) | Abdominal symptoms N (%) | Psychological symptoms N (%) | Neurological symptoms N (%) | Renal symptoms N (%) |
|---|---|---|---|---|---|---|
| June | 37 (37.8%) | 1 (1%) | 4 (4.1%) | 32 (32.7%) | 4 (4.1%) | 0 |
| July | 236 (44.7%) | 16 (3%) | 64 (12.1%) | 176 (33.3%) | 36 (6.8%) | 3 (.6%) |
| August | 216 (52.9%) | 11 (2.7%) | 43 (10.5%) | 150 (36.8%) | 36 (8.8%) | 1 (.2%) |
| September | 91 (42.5%) | 8 (3.7%) | 16 (7.5%) | 66 (30.8%) | 5 (2.3%) | 0 |
| October | 37 (38.5%) | 0 | 4 (4.2%) | 38 (39.6%) | 1 (1%) | 0 |
| November | 4 (40%) | 1 (10%) | 1 (10%) | 4 (40%) | 0 | 0 |
| .014* | .239 | .036* | .565 | .005* | .760 |
Chi-square test (P value <.05 significant)*.
Multi-nominal logistic regression analysis parameters with system-based post-discharge symptoms (N = 1354).
| Parameters | General symptoms | Cardio-respiratory symptoms | Abdominal symptoms | Psychological symptoms | Neurological symptoms | Renal symptoms | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AOR (CI) | AOR (CI) | AOR (CI) | AOR (CI) | AOR (CI) | AOR (CI) | |||||||
| Age (years) | ||||||||||||
| >60 | .91 | .54 | .98 | .98 | .75 | .28 | .81 | .19 | .52 | .07 | .52 | .96 |
| - < 60R | (.69–1.21) | (.41–2.33) | (.44–1.26) | (.60–1.10) | (.26–1.05) | (.37–4.08) | ||||||
| Condition on discharge | ||||||||||||
| With support | .97 | .92 | 1.23 | .83 | 1.46 | .53 | .98 | .96 | .61 | .37 | 6.26 | .01* |
| With No supportR | (.53–1.75) | (.16–9.34) | (.44–4.81) | (.53–1.84) | (.21–1.80) | (1.47–26.64) | ||||||
| Month of admission | ||||||||||||
| June–August | 1.21 | .08 | .94 | .86 | .83 | .32 | 1.13 | .30 | .90 | .67 | 1.52 | .23 |
| September–NovemberR | (.97–1.51) | (.47–1.85) | (.57–1.20) | (.89–1.42) | (.57–1.43) | (.70–3.33) | ||||||
| Diabetes mellitus | ||||||||||||
| Yes | .77 | .16 | 2.29 | .05* | .89 | .74 | 1.02 | .88 | 2.64 | .00* | .79 | .99 |
| NoR | (.53–1.11) | (1.97–5.40) | (.46–1.72) | (.70–1.50) | (1.46–4.77) | (.38–1.61) | ||||||
| Hypertension | ||||||||||||
| Yes | 1.21 | .50 | .85 | .87 | 1.6 | .24 | .77 | .43 | 1.22 | .73 | 1.58 | .48 |
| NoR | (.68–2.15) | (.11–6.42) | (.71–3.76 | (.41–1.46) | (.37–4.08) | (.43–5.80) | ||||||
AOR, adjusted odds ratio; CI, confidence interval. *P value <.05 is significant.